Rasagiline (Azilai) detailed instructions and medication guidance analysis

1. Introduction to drugs

Rasagiline (trade name: Azilect) is an oral selective monoamine oxidaseB inhibitor (MAO-B inhibitor), mainly used for the treatment of Parkinson's disease (PD). Its core function is to improve the motor symptoms of Parkinson's disease, such as resting tremor, muscle stiffness and bradykinesia, by inhibiting the degradation of dopamine in the brain and increasing the concentration of dopamine in the synaptic cleft. Compared with traditional dopamine receptor agonists or levodopa, rasagiline has the advantages of stable drug structure, convenient oral administration, and once-a-day administration. It also shows good efficacy in early and combination treatments.

Rasagiline is mainly suitable for two types of patients: first, as a monotherapy for patients with early-stage Parkinson's disease, improving the quality of life by delaying the progression of motor symptoms; second, as an adjuvant treatment for patients with mid-to-late stage Parkinson's disease, especially when combined with levodopa, it can reduce "on--off" fluctuations and improve exercise time.

2. Indications, usage and dosage

1.Indications

Monotherapy in patients with early-stage Parkinson's disease.

Combined with levodopa, it is used for patients with moderate to advanced Parkinson's disease who experience "on-off" phenomenon.

2.Usage and dosage

The usual dosage for adults is 1 mg once a day. It can be taken orally with water in the morning and is not affected by food.

Elderly patients usually do not need to adjust the dosage, but those with hepatic impairment should use caution or reduce the dosage.

When used in combination with levodopa, no dose adjustment is required, but drug interactions and side effects need to be observed.

3.Principles of dose adjustment

Contraindicated in patients with severe liver function impairment (Child-Pugh C grade).

For patients with moderate liver function impairment (Child-Pugh B grade), the recommended dose is 0.5 mg per day.

In patients with mild renal impairment, no dose adjustment is required, but renal function needs to be monitored.

3. Mechanism of action

Rasagiline selectively inhibits the activity of monoamine oxidase B (MAO-B), blocks the dopamine decomposition pathway, increases the level of dopamine in the brain, and thereby improves the motor symptoms of Parkinson's disease. In addition, research shows that rasagiline has a certain neuroprotective effect and may slow down the degenerative damage of dopaminergic neurons. However, the current neuroprotective effect still needs long-term clinical verification.

Compared with non-selective MAO inhibitors, rasagiline has less effect on MAO-A activity, so tyramine (tyramine) intake in food at conventional doses will not significantly cause hypertensive crisis, reducing the burden of drug and dietary restrictions.

4. Common side effects

1. Central nervous system: headache, insomnia, dizziness, anxiety, irritability.

2.Gastrointestinal reactions: nausea, constipation, indigestion.

3.Cardiovascular system: A small number of patients may experience mild elevation of blood pressure or tachycardia.

4.Rare reactions: muscle pain, abnormal dreams, hallucinations or impulse control disorders.

Most side effects are mild to moderate and can be tolerated or relieved by symptom management. Serious side effects are rare, but if cardiovascular symptoms or mental abnormalities occur, you should seek medical attention immediately and consider adjusting the dose or discontinuing the drug.

5. Medication precautions

1.Combined medication warning

Avoid concurrent use with otherMAO inhibitors, tricyclic antidepressants or selective 5-serotonin reuptake inhibitors (SSRIs) to avoid causing serotonin syndrome.

Caution should be exercised when using amphetamine-containing drugs (such as certain cold medicines and diet pills) at the same time.

2.Liver function monitoring

Liver function needs to be assessed before use, and those with abnormal liver function need regular monitoring.

If jaundice, obvious liver discomfort, or hematological abnormalities occur, the drug should be discontinued and medical treatment should be sought.

3.Guidance on daily life and medication

It is recommended to take medicine at a fixed time every day to improve compliance.

Observe changes in blood pressure and heart rate, and be careful to avoid dizziness or falls caused by standing up suddenly.

Reasonably arrange your work and rest, ensure sleep, and reduce central nervous system side effects.

4.Precautions for special groups of people

Elderly patients: often accompanied by a variety of chronic diseases, drug interactions should be paid attention to.

Pregnant women and lactating women: There is no sufficient data. In principle, it is contraindicated or used with caution after weighing the risks.

6. Patient management and follow-up recommendations

1. Efficacy evaluation: After taking the drug for several weeks, the improvement of motor symptoms, including tremor, stiffness and bradykinesia, needs to be evaluated.

2.Side effects record: Record dizziness, insomnia, gastrointestinal discomfort, etc. for the doctor to judge whether to adjust the dose.

3.Combined therapy management: If used in combination with levodopa, it is necessary to record the "on-off" time and symptom changes to help doctors optimize the dosage.

4.Regular review: It is recommended to review liver function and overall health every 3–6 months to ensure medication safety.

Rasagiline (Rasagiline), as a MAO-B selective inhibitor, has the effect of significantly improving the motor symptoms of Parkinson's disease, and has good tolerance and oral convenience. Reasonable usage and dosage, strict compliance with doctor's instructions and regular monitoring are the keys to ensuring efficacy and safety. Through observation of side effects and lifestyle management, patients can maintain quality of life while improving motor symptoms and achieve the goal of long-term management of Parkinson's disease.

Reference materials:https://www.drugs.com/